论文部分内容阅读
目的观察母牛分枝杆菌菌苗(M.Vaccne,简称微卡)在初治肺结核免疫治疗中的疗效及安全性。方法化疗开始使用微卡22.5μg,以注射用水化成1m l,深部肌注,10d 1次,连续3个月。化疗以9HRZ[异烟肼(H)0.3g、利福平(R)0.45g、吡嗪酰胺(Z)1.5g,每天1次,早晨空腹服用],出现肝功能异常者,待肝功能正常后改用力克肺疾片0.5g,1d3次。结果痰涂片阳性19例全部阴转。病灶变化:显效161例(92.5%);好转13例(7.5%);空洞55例,6个月内全部闭合。副反应:16例,其中药物性肝炎12例,微卡所致副反应4例,副反应发生率9.1%(16/175)。结论微卡能加快痰菌阴转、病灶吸收及空洞闭合速度,缩短化疗疗程。
Objective To observe the efficacy and safety of Mycobacterium vaccae vaccine (M. Vaccine) in the initial treatment of pulmonary tuberculosis. Methods Chemotherapy began using micro-card 22.5μg, 1ml injection for hydration, deep intramuscular injection, 10d 1 times, for 3 months. Chemotherapy in patients with abnormal liver function, with normal liver function, were treated with 9HRZ [0.3g of isoniazid (H), 0.45g of rifampicin (R) and 1.5g of pyrazinamide (Z) After switching to Lectra lung disease 0.5g, 1d3 times. Results of smear-positive 19 cases of all negative conversion. Changes in lesions: 161 cases markedly (92.5%); improved in 13 cases (7.5%); voids in 55 cases, all closed within 6 months. Side effects: 16 cases, including 12 cases of drug-induced hepatitis, micro-card side effects in 4 cases, the incidence of side effects 9.1% (16/175). Conclusion Micro-card can speed up sputum negative conversion, lesion absorption and empty closure speed, shorten the course of chemotherapy.